Evidence map›Paper›PMID 41862987›Full record

ArticleItalian journal of pediatrics2026

Multidisciplinary Delphi Consensus on management of children with moderate-severe atopic dermatitis.

Gian Luigi Marseglia, Maria Angela Tosca, Michele Miraglia Del Giudice, Anna Belloni Fortina, Domenico Bonamonte, Iria Neri, Diego G Peroni, Antonio D'Avino, Pasquale Comberiati, Cesare Filippeschi and 6 more

Abstract readConsensus StatementLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Italian journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Gian Luigi MarsegliaDepartment of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.
Maria Angela ToscaAllergy Center, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Michele Miraglia Del GiudiceDepartment of Woman, Child and General and Specialized Surgery, University of Campania "Luigi Vanvitelli", Naples, Italy.
Anna Belloni FortinaDermatology Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy.
Domenico BonamonteSection of Dermatology and Venereology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari "Aldo Moro", Bari, Italy.
Iria NeriDermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Diego G PeroniDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Antonio D'AvinoFIMP, Naples, Italy.
Pasquale ComberiatiDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Cesare FilippeschiDermatology Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
Sara MantiPediatric Unit, Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", University of Messina, Messina, Italy.
Elena GalliPediatric Allergy Unit, Research Center, San Pietro Hospital - Fatebenefratelli, Rome, Italy.
Francesca MoriAllergy Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
Carlo CaffarelliClinica Pediatrica, Department of Medicine and Surgery, Azienda Ospedaliero- Universitaria, University of Parma, Parma, Italy.
Amelia LicariDepartment of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.
Giorgio CiprandiAllergy Clinic, Casa di Cura Villa Montallegro, Via Monte Zovetto, 27, 16145, Genoa, Italy. gio.cip@libero.it.ORCID http://orcid.org/0000-0001-7016-8421

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atopic dermatitis is a compelling challenge in daily practice. Type 2 inflammation is the most common endotype in children and adolescents with AD. As a result, anti-inflammatory drugs, mainly corticosteroids (CS) and immunomodulatory agents, represent the first-line treatment to dampen type 2 inflammation. However, biologics, particularly dupilumab, dramatically changed the natural history of AD patients. A steering committee composed by expert pediatricians and dermatologists promoted a multidisciplinary Delphi Consensus to improve the knowledge about this topic. Experts in this field participated in the Consensus of three groups of statements concerning definition, diagnosis, and management. There was agreement for all proposed statements. The outcomes of the present multidisciplinary Delphi Consensus propose shared, evidence-based recommendations that may be fruitful in clinical practice.

Indexed as

Dermatitis, AtopicAdolescentAntibodies, Monoclonal, HumanizedChildDelphi TechniqueHumansSeverity of Illness IndexAntibodies, Monoclonal, HumanizeddupilumabAtopic dermatitisDupilumabItchPhenotypeSkin lesionsType 2 inflammation

Identifiers

PMID41862987
PMCPMC13005313

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.